Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis

NCT: NCT06589063 · RECRUITING

NCT IDNCT06589063
StatusRECRUITING
Start Date2024-03-01
Completion2037-12-31

Brief Summary

LOW-TAVR is a real-world, retrospective and prospective, multicenter Italian registry aimed at evaluating the characteristics and clinical outcomes of patients with severe low flow, low gradient aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) and, in particular: * risk factors * gender differences * comorbidities * pharmacological treatment * TAVR procedural characteristics * periprocedural and in-hospital complications * clinical outcome at 30-day, 1-year, 2-year and 5-year follow-up

Frequently Asked Questions

What is Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis?

Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis is a clinical trial registered under NCT06589063. Current status: RECRUITING.

What is the status of NCT06589063?

The current status of NCT06589063 (Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis) is: RECRUITING.

When did Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis start?

Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis started on 2024-03-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑